Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interferon-alpha 2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma
Autore:
Dillman, RO; Shea, WM; Tai, DF; Mahdavi, K; Barth, NM; Kharkar, BR; Poor, MM; Church, CK; DePriest, C;
Indirizzi:
Hoag Canc Ctr, Newport Beach, CA 92658 USA Hoag Canc Ctr Newport Beach CAUSA 92658 Ctr, Newport Beach, CA 92658 USA Bloomington Hosp, Bloomington, IN 47402 USA Bloomington Hosp Bloomington IN USA 47402 Hosp, Bloomington, IN 47402 USA Canc Biotherapy Res Grp, Cent Off, Franklin, TN 37068 USA Canc Biotherapy Res Grp Franklin TN USA 37068 Off, Franklin, TN 37068 USA
Titolo Testata:
NEURO-ONCOLOGY
fascicolo: 1, volume: 3, anno: 2001,
pagine: 35 - 41
SICI:
1522-8517(200101)3:1<35:I2A1AW>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL CARCINOMA; MALIGNANT GLIOMAS; GLIOBLASTOMA-MULTIFORME; BRAIN-TUMORS; INITIAL MANAGEMENT; THERAPY; RADIOTHERAPY; ASTROCYTOMAS; CHEMOTHERAPY; CARMUSTINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Dillman, RO Hoag Canc Ctr, 1 Hoag Dr,Bldg 41, Newport Beach, CA 92658 USA Hoag Canc Ctr 1 Hoag Dr,Bldg 41 Newport Beach CA USA 92658 USA
Citazione:
R.O. Dillman et al., "Interferon-alpha 2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma", NEURO-ONCOL, 3(1), 2001, pp. 35-41

Abstract

Interferon-alpha (IFN-alpha) has been safely given concurrently with radiation therapy (RT) in treating gliomas. As single agents, both IFN-alpha andcis-retinoic acid (CRA) have produced objective tumor regressions in patients with recurrent gliomas. In vitro, IFN-alpha 2a and CRA enhance radiation therapy effects on glioblastoma cells more than either agent alone. This trial was conducted to determine the clinical effects of IFN-alpha 2a and CRA when given concurrently with radiation therapy to patients with high-grade glioma. Newly diagnosed patients with high-grade glioma received IFN-alpha 2a at a dosage of 3 to 6 miuion IU s.c. 4 times a day for 3 days per week and 1 mg/kg CRA by mouth 4 times a day for 5 days per week during the delivery of partial brain radiation therapy at 180 cGy x 33 fractions for 5 days per week for a total of 59.4 Gy during the 7-week period. Use of the antiepileptic phenytoin was prohibited after observing that the combination ofIFN-alpha 2a, CRA, and phenytoin was associated with a high rate of dermatologic toxicity not seen in a previous study with concurrent IFN-alpha 2a and radiation therapy. Forty patients (26 men and 14 women) with a median age of 60 (range, 19 to sl years) were enrolled between August 1996 and October 1998. Histopathologic diagnoses were glioblastoma multiforme or grade 4 anaplastic astrocytoma in 36 patients, and grade 3 anaplastic astrocytoma in 4 patients. Only 4 patients (10%) underwent a gross total resection of tumor prior to this therapy; 50% were asymptomatic when treatment was initiated. The planned 7-week course of concurrent therapy was completed by 75% ofpatients; 30% completed the 16-week course of IFN-alpha and CRA alone. At a median follow-up of 36 months, there were 37 deaths, with a median overall survival of 9.3 months and a 1-year survival rate of 42%. There was no improvement in survival compared with a similar group of 19 patients treated with concurrent IFN-alpha 2a and radiation therapy in a previous trial. In the highrisk group of patients in the present study, concurrent treatment with IFN-alpha 2a, CRA, and RT was feasible, but was not associated with a better outcome compared with a similar patient population treated with radiation therapy and IFN-alpha 2a, or compared with radiation therapy alone in other trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:53:35